Latest Product Pipeline News

Pepper Money Limited reported a solid half-year performance with a 2% rise in net profit after tax and record assets under management of $20.1 billion. The company declared a 6.4 cent interim dividend, reflecting disciplined cost control and a positive outlook.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Anatara Lifesciences reported a 35% rise in net loss to $1.95 million for FY25, following pivotal Phase II trial results for its GaRP product that missed the primary efficacy endpoint but showed promising secondary benefits. The company is advancing commercialisation efforts and launching a new anti-obesity project amid tightened cash reserves.

Universal Biosensors updates investors on a shift from a secured loan to a potential entitlement offer, signaling evolving funding strategies and extended timelines.

Universal Biosensors reported a 44% increase in net loss to A$10.45 million for H1 2025, alongside an 11% revenue decline, raising serious going concern doubts. The company is pursuing an A$8.5 million senior secured loan and equity raise to sustain operations.

Swift Networks reports positive FY25 cash flow and EBITDA, secures new mining contracts, and progresses its next-generation Swift Access 2026 platform poised to accelerate growth.

Auric Mining wraps up its final gold processing campaign at Jeffreys Find with strong cash flow, while advancing mining and acquisitions at Munda and Higginsville to fuel growth.

Janus Electric Holdings has relaunched on the ASX, securing $8.8 million to accelerate its heavy vehicle electrification strategy, including a key supply agreement with Electrovaya for next-generation lithium-ion batteries.

EZZ Life Science Holdings marked a pivotal quarter with the launch of its EZZDAY brand in the US, a significant Southeast Asia distribution agreement, and expanded domestic retail presence, driving a 46% jump in customer receipts.

Anatara Lifesciences has received nearly $1 million from the Australian Government’s R&D tax incentive, providing a vital capital injection to advance its Anti-Obesity pre-clinical studies.

Nuchev Limited reports a record-breaking Q4 FY25 with revenues soaring 167% year-on-year, driven by strong growth across multiple markets and a strategic agency agreement in Australia.

Dreadnought Resources has identified a large, open gold-in-soil anomaly at Steve’s Reward within its 100% owned Mangaroon Gold Project in Western Australia, with drilling underway and assay results expected soon.